Charles River Laboratories International, Inc. (NYSE:CRL) Position Trimmed by Toronto Dominion Bank

Toronto Dominion Bank lessened its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 32.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,336 shares of the medical research company's stock after selling 8,281 shares during the quarter. Toronto Dominion Bank's holdings in Charles River Laboratories International were worth $3,200,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Rafferty Asset Management LLC raised its stake in Charles River Laboratories International by 5.5% in the 4th quarter. Rafferty Asset Management LLC now owns 6,860 shares of the medical research company's stock valued at $1,266,000 after purchasing an additional 360 shares during the last quarter. Quantinno Capital Management LP raised its stake in Charles River Laboratories International by 78.4% in the 4th quarter. Quantinno Capital Management LP now owns 36,930 shares of the medical research company's stock valued at $6,817,000 after purchasing an additional 16,224 shares during the last quarter. Mufg Securities Americas Inc. acquired a new position in Charles River Laboratories International in the 4th quarter valued at about $139,000. Man Group plc raised its stake in Charles River Laboratories International by 359.4% in the 4th quarter. Man Group plc now owns 82,390 shares of the medical research company's stock valued at $15,209,000 after purchasing an additional 64,456 shares during the last quarter. Finally, Nomura Holdings Inc. acquired a new position in Charles River Laboratories International in the 4th quarter valued at about $56,820,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president now directly owns 19,513 shares of the company's stock, valued at $2,837,385.33. This represents a 2.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Mizuho cut their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. Robert W. Baird boosted their target price on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. Evercore ISI raised shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price for the company in a research note on Thursday, May 8th. JPMorgan Chase & Co. lowered their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Finally, The Goldman Sachs Group cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price target for the company from $190.00 to $170.00 in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $171.85.

Charles River Laboratories International Trading Down 1.3%

Shares of NYSE:CRL traded down $1.76 during trading on Wednesday, reaching $136.89. 95,165 shares of the stock were exchanged, compared to its average volume of 989,658. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The firm has a market cap of $6.72 billion, a price-to-earnings ratio of 912.50, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The firm's 50-day moving average price is $130.77 and its 200 day moving average price is $162.06.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International's quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.27 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).